SPL 1.57% 9.4¢ starpharma holdings limited

The 505(b)(2) route was always just a hopeful furphy. The ASCO...

  1. 3,353 Posts.
    lightbulb Created with Sketch. 800
    The 505(b)(2) route was always just a hopeful furphy.

    The ASCO abstract for DEP-Irinotecan (which is supposedly the most advanced candidate now) stated this in the conclusion:
    ’warrants further clinical assessment’

    And yes, I have noted that the captain of team brown has started the day with three brand new threads. The pump is on. Again. However he’s conveniently ignored all the bad news dump from Wednesday’s webinar.

    Laughable.
 
watchlist Created with Sketch. Add SPL (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.